person · Reporting owner

Wainman Paul R

Disclosed activity across 1 company

Tapewire entity: 52349
SEC CIK: 0001603581

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IMMUCELL CORP /DE/ICCC · Entity 6837	Director	April 15, 2026	April 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IMMUCELL CORP /DE/

Report date April 15, 2026 · Filed April 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-04-15	Direct	11,933	Reported balance After 2026-04-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-15 · Grant · Acquired 11,933 · Balance 11,933 F1: The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 15, 2026 Filed Apr 16, 2026 19:57 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	GrantNon Qualified Stock Options (Right to buy) · Derivative	11,933	$0.00 Strike: $7.60	$0.00	Disclosure SEC source: 0001437749-26-012551 · rdgdoc.xml · derivative · entry 1 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,933 Underlying: Common Stock · 11,933 shares Expires 2036-04-15 F1 · derivative.exercise_date: The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029. Read SEC document
April 16, 2025 Filed Apr 14, 2026 19:39 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	GrantNon Qualified Stock Options (Right to buy) · Derivative	10,000	$0.00 Strike: $5.49	$0.00	Disclosure SEC source: 0001437749-26-012238 · rdgdoc.xml · derivative · entry 1 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-04-16 Read SEC document
September 20, 2024 Filed Sep 24, 2024 12:31 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	GrantNon Qualified Stock Options (Right to buy) · Derivative	10,000	$3.60 Strike: $3.60	$36,000.00	Disclosure SEC source: 0001213900-24-081210 · marketforms-67039.xml · derivative · entry 1 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-20 Read SEC document
December 15, 2022 Filed Jan 24, 2023 23:27 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	GrantNon Qualified Stock Options (Right to buy) · Derivative	10,000	$6.52 Strike: $6.52	$65,200.00	Disclosure SEC source: 0001213900-23-004914 · ownership.xml · derivative · entry 1 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-12-15 Read SEC document
June 17, 2021 Filed Jun 21, 2021 18:24 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	GrantIncentive Stock Options (Right to buy) · Derivative	10,000	$10.04 Strike: $10.04	$100,400.00	Disclosure SEC source: 0001213900-21-033244 · ownership.xml · derivative · entry 1 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-06-17 Read SEC document
March 11, 2019 Filed Mar 13, 2019 13:10 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	Disposition to issuerIncentive Stock Options (Right to buy) · Derivative	10,731	$4.80 Strike: $4.80	$51,508.80	Disclosure SEC source: 0001213900-19-004013 · doc4.xml · derivative · entry 2 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,731 shares Expires 2019-03-31 Read SEC document
March 11, 2019 Filed Mar 13, 2019 13:10 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	GrantCommon Stock, par value $0.10 per share	4,269	$4.80	$20,491.20	Disclosure SEC source: 0001213900-19-004013 · doc4.xml · nonDerivative · entry 1 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,269 Read SEC document
March 19, 2018 Filed Mar 21, 2018 18:11 UTC	IMMUCELL CORP /DE/ ICCC · Entity 6837	GrantIncentive Stock Options (Right to buy) · Derivative	15,000	$7.08 Strike: $7.08	$106,200.00	Disclosure SEC source: 0001213900-18-003257 · doc4.xml · derivative · entry 1 Wainman Paul R · CIK 0001603581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-19 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.